1. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs. Abner, E., M. Stoszko, L. Zeng, H.C. Chen, A. Izquierdo-Bouldstridge, T. Konuma, E. Zorita, E. Fanunza, Q. Zhang, T. Mahmoudi, M.M. Zhou, G.J. Filion, and A. Jordan. Journal of Virology, 2018. 92(10): e02056-02017. PMID[29343578].
[PubMed]. HIV_04_2018.
2. Evaluation of the Fusion Inhibitor P3 Peptide as a Potential Microbicide to Prevent HIV Transmission in Women. Bartolo, I., A.R. Diniz, P. Borrego, J.P. Ferreira, M.R. Bronze, H. Barroso, R. Pinto, C. Cardoso, J.F. Pinto, R.C. Diaz, P.G. Broncano, M.A. Munoz-Fernandez, and N. Taveira. Plos One, 2018. 13(4): e0195744. PMID[29668740].
[PubMed]. HIV_04_2018.
3. Design and Synthesis of Bicyclic Piperazine Sulfonamides Leading to Highly Potent HIV Protease Inhibitors. Bungard, C. Abstracts of Papers of the American Chemical Society, 2017. 254. ISI[000429556701284].
[WOS]. HIV_04_2018.
4. Induction of Autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 Inhibitors Suppresses HIV-1 Replication. Campbell, G.R., R.S. Bruckman, S.D. Herns, S. Joshi, D.L. Durden, and S.A. Spector. The Journal of Biological Chemistry, 2018. 293(16): p. 5808-5820. PMID[29475942]. PMCID[PMC5912471].
[PubMed]. HIV_04_2018.
5. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants. Delino, N.S., M. Aoki, H. Hayashi, S.I. Hattori, S.B. Chang, Y. Takamatsu, C.D. Martyr, D. Das, A.K. Ghosh, and H. Mitsuya. Antimicrobial Agents and Chemotherapy, 2018. 62(5): e02060-02017. PMID[29463535].
[PubMed]. HIV_04_2018.
6. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-dependent Cellular Cytotoxicity Cross-clade and Cooperates with gp41-specific IgG to Increase Cell Lysis. Duchemin, M., M. Khamassi, L. Xu, D. Tudor, and M. Bomsel. Frontiers in Immunology, 2018. 9(244): 12pp. PMID[29651286]. PMCID[PMC5884934].
[PubMed]. HIV_04_2018.
7. Synthesis and Evaluation of Substituted 4-Arylimino-3-hydroxybutanoic acids as Potential HIV-1 Integrase Inhibitors. Faridoon, D. Mnkandhla, M. Isaacs, H.C. Hoppe, and P.T. Kaye. Bioorganic & Medicinal Chemistry Letters, 2018. 28(6): p. 1067-1070. PMID[29482943].
[PubMed]. HIV_04_2018.
8. Bispecific Chimeric Antigen Receptors Targeting the CD4 Binding Site and High-mannose Glycans of gp120 Optimized for anti-Human Immunodeficiency Virus Potency and Breadth with Minimal Immunogenicity. Ghanem, M.H., S. Bolivar-Wagers, B. Dey, A. Hajduczki, D.A. Vargas-Inchaustegui, D.T. Danielson, V. Bundoc, L. Liu, and E.A. Berger. Cytotherapy, 2018. 20(3): p. 407-419. PMID[29306566].
[PubMed]. HIV_04_2018.
9. Design of Highly Potent, Dual-acting and Central-nervous-system-penetrating HIV-1 Protease Inhibitors with Excellent Potency against Multidrug-resistant HIV-1 Variants. Ghosh, A.K., K.V. Rao, P.R. Nyalapatla, S. Kovela, M. Brindisi, H.L. Osswald, B. Sekhara Reddy, J. Agniswamy, Y.F. Wang, M. Aoki, S.I. Hattori, I.T. Weber, and H. Mitsuya. ChemMedChem, 2018. 13(8): p. 803-815. PMID[29437300]. PMCID[PMC5912973].
[PubMed]. HIV_04_2018.
10. Discovery and Validation of 2-Styryl Substituted Benzoxazin-4-ones as a Novel Scaffold for Rhomboid Protease Inhibitors. Goel, P., T. Jumpertz, A. Ticha, I. Ogorek, D.C. Mikles, M. Hubalek, C.U. Pietrzik, K. Strisovsky, B. Schmidt, and S. Weggen. Bioorganic & Medicinal Chemistry Letters, 2018. 28(8): p. 1417-1422. PMID[29463448].
[PubMed]. HIV_04_2018.
11. A Structure-based Design Approach to Advance the Allyltyrosine-based Series of HIV Integrase Inhibitors. Gordon, C.P., N. Dalton, N. Vandegraaff, J. Deadman, D.I. Rhodes, J.A. Coates, S.G. Pyne, R. Griffith, J.B. Bremner, and P.A. Keller. Tetrahedron, 2018. 74(12): p. 1253-1268. ISI[000427665200013].
[WOS]. HIV_04_2018.
12. Synthesis of 3'-Halo-5'-norcarbocyclic nucleoside phosphonates as Potent anti-HIV Agents. Hamon, N., M. Kaci, J.P. Uttaro, C. Perigaud, and C. Mathe. European Journal of Medicinal Chemistry, 2018. 150: p. 642-654. PMID[29558735].
[PubMed]. HIV_04_2018.
13. First Discovery of a Potential Carbonate Prodrug of NNRTI Drug Candidate RDEA427 with Submicromolar Inhibitory Activity against HIV-1 K103N/Y181C Double Mutant Strain. Huang, B.S., X.H. Liu, Y. Tian, D.W. Kang, Z.X. Zhou, D. Daelemans, C.E. De, C. Pannecouque, P. Zhan, and X.Y. Liu. Bioorganic & Medicinal Chemistry Letters, 2018. 28(8): p. 1348-1351. PMID[29534929].
[PubMed]. HIV_04_2018.
14. Eudesmanolides and Other Constituents from the Flowers of Wedelia trilobata. Hui, Y., J. Cao, J. Lin, J.N. Yang, Y.J. Liu, C.R. Han, X.P. Song, C.Y. Dai, X.P. Zhang, W.H. Chen, and G.Y. Chen. Chemistry & Biodiversity, 2018. 15(3): e1700411. PMID[29369483].
[PubMed]. HIV_04_2018.
15. An RNA-binding Compound That Stabilizes the HIV-1 gRNA Packaging Signal Structure and Specifically Blocks HIV-1 RNA Encapsidation.Ingemarsdotter, C.K., J.W. Zeng, Z.Q. Long, A.M.L. Lever, and J.C. Kenyon. Retrovirology, 2018. 15(25): 14pp. PMID[29540207]. PMCID[PMC5853050].
[PubMed]. HIV_04_2018.
16. Synthesis of 4'-Substituted purine 2'-deoxynucleosides and their Activity against Human Immunodeficiency Virus Type 1 and Hepatitis B Virus. Kohgo, S., S. Imoto, R. Tokuda, Y. Takamatsu, N. Higashi-Kuwata, M. Aoki, M. Amano, H. Kansui, K. Onitsuka, K. Maeda, and H. Mitsuya. ChemistrySelect, 2018. 3(11): p. 3313-3317. ISI[000428379500059].
[WOS]. HIV_04_2018.
17. Pharmacophore Requirements for HIV-1 Reverse Transcriptase Inhibitors That Selectively "Freeze" the Pre-translocated Complex During the Polymerization Catalytic Cycle. Lacbay, C.M., M. Menni, J.A. Bernatchez, M. Gotte, and Y.S. Tsantrizos. Bioorganic & Medicinal Chemistry, 2018. 26(8): p. 1713-1726. PMID[29478802].
[PubMed]. HIV_04_2018.
18. The anti-Caspase Inhibitor Q-VD-OPH Prevents AIDS Disease Progression in SIV-Infected Rhesus Macaques. Laforge, M., R. Silvestre, V. Rodrigues, J. Garibal, L. Campillo-Gimenez, S. Mouhamad, V. Monceaux, M.C. Cumont, H. Rabezanahary, A. Pruvost, A. Cordeiro-da-Silva, B. Hurtrel, G. Silvestri, A. Senik, and J. Estaquier. The Journal of Clinical Investigation, 2018. 128(4): p. 1627-1640. PMID[29553486]. PMCID[PMC5873886].
[PubMed]. HIV_04_2018.
19. Design, Synthesis, and Structure-Activity-Relationship of a Novel Series of CXCR4 Antagonists. Li, Z., Y. Wang, C. Fu, X. Wang, J.J. Wang, Y. Zhang, D. Zhou, Y. Zhao, L. Luo, H. Ma, W. Lu, J. Zheng, and X. Zhang. European Journal of Medicinal Chemistry, 2018. 149: p. 30-44. PMID[29494843].
[PubMed]. HIV_04_2018.
20. The Discovery of Novel Diarylpyri(mi)dine Derivatives with High Level Activity against a Wide Variety of HIV-1 Strains as Well as against HIV-2. Lu, X.Y., J.P. Yang, D.W. Kang, P. Gao, D. Daelemans, C.E. De, C. Pannecouque, P. Zhan, and X.Y. Liu. Bioorganic & Medicinal Chemistry, 2018. 26(8): p. 2051-2060. PMID[29559197].
[PubMed]. HIV_04_2018.
21. Anti-HIV Activity of New Higher Order G-quadruplex Aptamers Obtained from Tetra-end-linked Oligonucleotides. Nici, F., G. Oliviero, A.P. Falanga, S. D'Errico, M. Marzano, D. Musumeci, D. Montesarchio, S. Noppen, C. Pannecouque, G. Piccialli, and N. Borbone. Organic & Biomolecular Chemistry, 2018. 16(13): p. 2349-2355. PMID[29543291].
[PubMed]. HIV_04_2018.
22. Novel HIV-1 Protease Inhibitors: Design, Synthesis, and Biological Evaluation. Osswald, H. Abstracts of Papers of the American Chemical Society, 2017. 254. ISI[000429556701349].
[WOS]. HIV_04_2018.
23. Counteracting Akt Activation by HIV Protease Inhibitors in Monocytes/Macrophages.Pasquereau, S., A. Kumar, W. Abbas, and G. Herbein. Viruses, 2018. 10(4): E190. PMID[29652795]. PMCID[PMC5923484].
[PubMed]. HIV_04_2018.
24. Molecular Dynamics and MM/GBSA-Integrated Protocol Probing the Correlation between Biological Activities and Binding Free Energies of HIV-1 TAR RNA Inhibitors. Peddi, S.R., S.K. Sivan, and V. Manga. Journal of Biomolecular Structure & Dynamics, 2018. 36(2): p. 486-503. PMID[28081678].
[PubMed]. HIV_04_2018.
25. Structure-guided Approach Identifies a Novel Class of HIV-1 Ribonuclease H Inhibitors: Binding Mode Insights through Magnesium Complexation and Site-directed Mutagenesis Studies. Poongavanam, V., A. Corona, C. Steinmann, L. Scipione, N. Grandi, F. Pandolfi, S.R. Di, R. Costi, F. Esposito, E. Tramontano, and J. Kongsted. MedChemComm, 2018. 9(3): p. 562-575. ISI[000428670100016].
[WOS]. HIV_04_2018.
26. Second Generation HIV-1 Maturation Inhibitors: The Discovery of BMS-955176.Regueiro-Ren, A. Abstracts of Papers of the American Chemical Society, 2017. 254. ISI[000429556701355].
[WOS]. HIV_04_2018.
27. Silibinin phosphodiester glyco-conjugates: Synthesis, Redox Behaviour and Biological Investigations.Romanucci, V., C. Agarwal, R. Agarwal, C. Pannecouque, M. Iuliano, G. De Tommaso, T. Caruso, G. Di Fabio, and A. Zarrelli. Bioorganic Chemistry, 2018. 77: p. 349-359. PMID[29421711].
[PubMed]. HIV_04_2018.
28. Synthesis and Antiretroviral Activity of 6-Acetyl-coumarin Derivatives against HIV-1 Infection.Srivastav, V.K., M. Tiwari, X. Zhang, and X.J. Yao. Indian Journal of Pharmaceutical Sciences, 2018. 80(1): p. 108-117. ISI[000429314100011].
[WOS]. HIV_04_2018.
29. Identifying and Characterizing Therapeutic Antagonists to HIV Tat Protein. Steiner, J., N. Geiger, W.X. Li, R. Tyagi, M. Bachani, N. Malik, and A. Nath. Journal of Neuroimmune Pharmacology, 2018. 13: p. S82-S82. ISI[000429149100283].
[WOS]. HIV_04_2018.
30. IFN-lambda 4 Inhibits HIV Infection of Macrophages by Signaling through IFN-lambda R1/IL-10R2 Receptor Complex. Su, Q.J., X. Wang, R.H. Zhou, L. Guo, H. Liu, J.L. Li, and W.Z. Ho. Journal of Neuroimmune Pharmacology, 2018. 13: p. S83-S83. ISI[000429149100285].
[WOS]. HIV_04_2018.
31. Inhibition of NF-kappaB-dependent HIV-1 Replication by the Marine Natural Product Bengamide A. Tietjen, I., D.E. Williams, S. Read, X.T. Kuang, P. Mwimanzi, E. Wilhelm, T. Markle, N.N. Kinloch, C.N. Naphen, K. Tenney, T. Mesplede, M.A. Wainberg, P. Crews, B. Bell, R.J. Andersen, Z.L. Brumme, and M.A. Brockman. Antiviral Research, 2018. 152: p. 94-103. PMID[29476895].
[PubMed]. HIV_04_2018.
32. Optimization of Polycistronic anti-CCR5 Artificial microRNA Leads to Improved Accuracy of Its Lentiviral Vector Transfer and More Potent Inhibition of HIV-1 in CD4(+) T-Cells. Urusov, F., D. Glazkova, D. Omelchenko, E. Bogoslovskaya, G. Tsyganova, K. Kersting, G. Shipulin, and V. Pokrovsky. Cells, 2018. 7(2): E10. PMID[29401717]. PMCID[PMC5850098].
[PubMed]. HIV_04_2018.
33. Antiviral Effects of Ferric Ammonium citrate. Wang, H.B., Z. Li, J.L. Niu, Y.F. Xu, L. Ma, A.L. Lu, X. Wang, Z.K. Qian, Z. Huang, X. Jin, Q.B. Leng, J.H. Wang, J. Zhong, B. Sun, and G.X. Meng. Cell Discovery, 2018. 4(14): 11pp. PMID[29619244]. PMCID[PMC5871618].
[PubMed]. HIV_04_2018.
34. Synthesis of Novel Sugar or Azasugar Modified Anthra[1,2-d]imidazole-6,11-dione Derivatives and Biological Evaluation. Wang, Q.W., C. Ma, X.Y. Li, X.F. Wang, R.X. Rong, C. Wei, P.Z. Zhang, and X.L. Li. Carbohydrate Research, 2018. 460: p. 29-33. PMID[29501861].
[PubMed]. HIV_04_2018.
35. A Lanthipeptide Library Used to Identify a Protein-protein Interaction Inhibitor. Yang, X., K.R. Lennard, C. He, M.C. Walker, A.T. Ball, C. Doigneaux, A. Tavassoli, and W.A. van der Donk. Nature Chemical Biology, 2018. 14(4): p. 375-380. PMID[29507389]. PMCID[PMC5866752].
[PubMed]. HIV_04_2018.
36. ONC201 Inhibits HIV-1 Replication in Human Macrophages via FOXO3A and TNFSF10. Zhao, R.Z., Y.L. Huang, and J.L. Zheng. Journal of Neuroimmune Pharmacology, 2018. 13: p. S95-S95. ISI[000429149100329].
[WOS]. HIV_04_2018.
37. A Neutralizing Antibody Recognizing Primarily N-linked Glycan Targets the Silent Face of the HIV Envelope. Zhou, T.Q., A.Q. Zheng, U. Baxa, G.Y. Chuang, I.S. Georgiev, R. Kong, S. O'Dell, S. Shahzad-Ul-Hussan, C.H. Shen, Y. Tsybovsky, R.T. Bailer, S.K. Gift, M.K. Louder, K. McKee, R. Rawi, C.H. Stevenson, G.B.E. Stewart-Jones, J.D. Taft, E. Waltari, Y.P. Yang, B.S. Zhang, S.S. Shivatare, V.S. Shivatare, C.C.D. Lee, C.Y. Wu, J.C. Mullikin, C.A. Bewley, D.R. Burton, V.R. Polonis, L. Shapiro, C.H. Wong, J.R. Mascola, P.D. Kwong, X.L. Wu, and C.S. Nisc. Immunity, 2018. 48(3): p. 500-513. PMID[29548671].
[PubMed]. HIV_04_2018.
38. Exceptional Potency and Structural Basis of a T1249-derived Lipopeptide Fusion Inhibitor against HIV-1, HIV-2, and Simian Immunodeficiency Virus. Zhu, Y., X. Zhang, X. Ding, H. Chong, S. Cui, J. He, X. Wang, and Y. He. The Journal of biological chemistry, 2018. 293(14): p. 5323-5334. PMID[29425101]. PMCID[PMC5892594].
[PubMed]. HIV_04_2018.
Patent Citations
39. Prodrugs of Fluorinated acyclic nucleoside phosphonates. Andrei, G., S. De Jonghe, E. Groaz, P. Herdewijn, M. Luo, D. Schols, and R. Snoeck. Patent. 2018. 2017-EP73988 2018055071: 81pp.
[Patent]. HIV_04_2018.
40. C-3 Triterpenone with C-17 Reverse Amide Derivatives as HIV Inhibitors. Bandi, P.R., R.R. Kura, D.K. Gazula Levi, B.R. Kasireddy, C. Thomas Wild, D. Eugene Martin, and T. John Nitz. Patent. 2018. 2017-IB56145 2018065930: 48pp.
[Patent]. HIV_04_2018.
41. Preparation of Benzothiazol-6-ylacetic acid Derivatives and Their Use for Treating HIV Infection.Cai, Z.R., H. Guo, M. Ji, H. Jin, A. Lee, R. McFadden, M.L. Mitchell, M. Munoz, H.-J. Pyun, L. Xu, and H. Yang. Patent. 2018. 2017-US53563 2018064080: 397pp.
[Patent]. HIV_04_2018.
42. Oligonucleotides Containing 2'-Deoxy-2'fluoro-Β-D-arabinose nucleic acid (2'-Fana) for Treatment and Diagnosis of Retroviral Diseases. Rossi, J.J., M.J. Damha, V. Aishwarya, M. Takahashi, and H. Li. Patent. 2018. 2017-US53127 2018058006: 52pp.
[Patent]. HIV_04_2018.